Skip to main content

Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China

Abstract

Clinical features and outcomes of FL patients in Chinese population are limited, thus promoting us to perform this analysis on a large cohort of 1845 patients with FL enrolled from nine medical centers nationwide in China. In this cohort, the median age of patients at diagnosis was 53 years, which was comparable to that reported previously for Chinese FL patients (49–51 years) but younger than that for Western FL patients (60–65 years). In contrast with Western patients, Chinese FL patients more likely involved extranodal sites but less frequently infiltrated bone marrow. Other clinical characteristics were comparable between two populations. In this study, 91% of patients were managed with chemotherapy, yielding 72% and 46% of overall-response rate and complete remission. After median 55-month follow-up, 5-year progressive-free and overall survival were 61% and 89%, respectively. Both were analogous to those reported in prior Chinese and Western studies. Consistent with published data, addition of rituximab into both induction (Ri) and maintenance (Rm) treatment led to the most favorable outcomes. Interestingly, Ri only had better outcomes than Rm only. Notably, 7% of patients experienced histologic transformation (HT) and correlated with poor survival. Of the transformed FL cases, 3% and 4% of HT events occurred prior to or post-treatment, respectively. Importantly, the latter displayed worse outcomes than the former. Altogether, this study provides real-world information of the largest cohort of FL patients so far in China, which might lay a foundation for clinical investigation of Chinese FL in future.

To the editor,

Follicular lymphoma (FL), a common indolent B-cell lymphoma, is characterized by its high heterogeneity in clinical characteristics and outcomes [1]. Demographics, clinical characteristics, treatment patterns and outcomes of FL patients have been well documented in Western countries [2, 3]. However, this information is largely lacking in China. To understand clinical presentations, treatments and prognosis of Chinese FL patients, we performed a retrospective multicenter study, which enrolled 1845 patients (age > 18 years) with newly diagnosed FL between 2000 and 2020 in China. Patients and methods for this study are described in detail in Additional file 1.

Demographics and clinical characteristics of the patients enrolled in this study are summarized in Table 1. The median age at diagnosis was 53 years in our cohort, similar to that reported earlier for Chinese FL patients (49–51 years) but much younger than that reported in Western cohorts (60–65 years) [2,3,4,5]. Consistent with the prior study from China [4], Chinese FL patients had relatively lower rate of ECOG ≤ 1 than non-Chinese counterparts, reflecting poor performance status; moreover, approximately 40% of Chinese FL patients had extranodal involvement sites of > 1, significantly higher than that demonstrated in the cohorts of Western countries (5–25%) [2, 3]. Although the incidence of bone-marrow infiltration (BMI) in this cohort (28%) was higher than that reported previously for Chinese FL patients (15.2%) [4], the BMI rates in Chinese FL patients were lower than that in Western patients (29–52%) [2,3,4]. Other clinical features of FL patients in our cohort were comparable to those reported for Chinese FL patients and in the Western cohorts [2,3,4,5].

Table 1 Baseline patient and disease characteristics in the entire cohort (n = 1845)

Treatment patterns and therapeutic responses are detailed in Additional file 2. In our cohort, 91% of FL patients received systemic chemotherapies, among which CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) ± rituximab (R) was the most frequently used regimen, probably representing the major regimen for frontline treatment of FL in China, in accordance with the earlier report [4]. However, only 1% of patients received bendamustine plus rituximab, due to unavailability of bendamustine in China until 2019 [6]. Unlike approximately 20% of FL patients treated with observation in the cohorts of Western countries [7], only 7% of Chinese FL patients were administered with watchful waiting. In the study, overall response rate (ORR) was 72% with 46% complete remission (CR). 5-year progressive-free (PFS) and overall survival (OS) for all patients were 61% and 89%, respectively (Fig. 1A, B). Both were analogous to those observed previously in Chinese FL patients and several Western cohorts [4, 8, 9]. We found that rituximab-based induction therapy (Ri) followed by rituximab maintenance (Rm) resulted in the best outcomes (both PFS and OS), consistent with the findings from another real-world study in Chinese population [10]. Ri only was superior to Rm only (Fig. 1C, D). This observation suggests that incorporating rituximab into induction treatment might be more beneficial than using rituximab for maintenance if patients could not afford long-term usage of this costly agent.

Fig. 1
figure1

Clinical prognostic analysis of Chinese FL patients in the entire cohort and different subgroups. A, B 5-year progression-free survival (PFS, A) and overall survival (OS, B) of Chinese FL population in the whole cohort. C, D Kaplan–Meier curves of PFS (C) and OS (D) according to different rituximab administrations (no rituximab treatments (No R), first-line induction chemotherapies with rituximab (Ri), maintenance with rituximab (Rm), and Ri plus Rm regimens). E OS for patients with or without histological transformation (HT). F OS for patients with HT prior to or post-treatment

Histological transformation (HT) represents a crucial feature of FL and correlates with unfavorable outcomes [11]. Transformed FL (t-FL) can happen prior to or post-chemotherapy [12]. In our cohort, 125 patients (7%) experienced HT, of which 3% and 4% of transformed cases were observed prior to or post-treatment, respectively. Analogous to those described in previous studies involving Western countries, patients with t-FL displayed poorer outcomes than those with non-transformed FL (nt-FL; Fig. 1E; P = 0.0002). In this study, patients with t-FL prior to treatment had 87% of 5-year OS, which was similar to those with nt-FL but significantly better than those whose disease was transformed post-chemotherapy (Fig. 1F; P = 0.040). This observation suggests that patients with t-FL prior to therapy could be treated as those with nt-FL, but intensive chemotherapies should be administrated for patients with t-FL post-therapy.

This study reveals that Chinese FL patients were much younger and had higher extranodal involvement but lower BM infiltration than Western FL patients. Most Chinese FL patients received systemic chemotherapies, with CHOP ± R representing the most common regimen. In terms of ORR, CR, PFS and OS of FL patients, no significant difference was observed between our cohort and the cohorts previously reported in China and Western countries. Ri plus Rm yielded the most favorable outcome, while Ri only was superior to Rm only when they were applied separately. 7% of FL patients underwent HT, of which 3% and 4% of cases transformed prior to or post-chemotherapy. The latter had poorer outcome than the former. Collectively, this large retrospective study outlines the clinical features and outcomes of Chinese FL patients, which might lay a foundation for future clinical investigation of FL in China.

Availability of data and materials

All datasets supporting the conclusions of this study are included in the figures, tables and additional files.

Abbreviations

FL:

Follicular lymphoma

ORR:

Overall response rate

CR:

Complete remission

HT:

Histologic transformation

PFS:

Progressive-free survival

OS:

Overall survival

t-FL:

Transformed follicular lymphoma

CHOP:

Cyclophosphamide, doxorubicin, vincristine and prednisone

BR:

Bendamustine plus rituximab

R i :

Rituximab-based induction therapy

R m :

Rituximab maintenance

nt-FL:

Non-transformed FL

References

  1. 1.

    Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316–27.

    CAS  Article  Google Scholar 

  2. 2.

    Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood. 2000;95(3):783–9.

    CAS  PubMed  Google Scholar 

  3. 3.

    Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol. 2015;170(1):85–95.

    CAS  Article  Google Scholar 

  4. 4.

    Zhou Y, Qin Y, He X, Liu P, Yang J, Zhou L, et al. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: a China single-center retrospective study. Asia Pac J Clin Oncol. 2021;17(3):289–99.

    Article  Google Scholar 

  5. 5.

    Song Y, Zhang H, Yang H, Liu A, Cen X, Zhu J, Wen Y, et al. Baseline characteristics of 3046 non-Hodgkin’s lymphoma patients diagnosed between July 2015 and May 2018: a report from China Lymphoma Patient Registry (CLAP). Blood. 2018;132(Supplement 1):5394.

    Article  Google Scholar 

  6. 6.

    Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020;136(23):2628–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, et al. Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era. Br J Haematol. 2016;172(5):724–34.

    CAS  Article  Google Scholar 

  8. 8.

    Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984–91.

    CAS  Article  Google Scholar 

  9. 9.

    Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506–13.

    CAS  Article  Google Scholar 

  10. 10.

    Huang HH, Wen YC, Chen HM, Hsiao FY, Ko BS. Rituximab maintenance improves overall survival in follicular lymphoma: a retrospective nationwide real-world analysis from Taiwan Cancer Registry Database. Cancer Med. 2018;7(8):3582–91.

    CAS  Article  Google Scholar 

  11. 11.

    Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood. 2015;125(1):40–7.

    CAS  Article  Google Scholar 

  12. 12.

    Rusconi C, Anastasia A, Chiarenza A, Marcheselli L, Cavallo F, Rattotti S, et al. Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL). Br J Haematol. 2019;185(4):713–7.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank all physicians, nurses, and particularly patients involved in this study at nine medical centers. Especially, we also thank Prof. Tongyu Lin (Sichuan Cancer Hospital) for his kind supervision and support in designing and conducting this study. In addition, we deeply appreciate the Chinese Workshop on Follicular Lymphoma to provide pivotal suggestions and support this work.

Funding

This work was financially supported by the National Natural Science Foundation of China (Nos. 81770126, 81770161, 81800163), the Fujian Natural Science Foundation of China (No. 2020J011246), the Xiamen Municipal Bureau of Science and Technology (No. 3502Z20209003) and the Lymphoma Research Fund of Chinese Anti-Cancer Association (No. CORP-117).

Author information

Affiliations

Authors

Contributions

JZ, LYF, ZML, YQS, BX took part in conception and design. JZ, LYF, SHY, HFY, ZZ involved in research performance. JZ, LYF, SHY, HFY, ZZ, WX, MMD, ZJL, ZFL, LYP, XHH, FLC, YX, BYC, HLZ, LW, KYD, WYL, HYY, WLZ, LGQ, ZML, YQS, BX took part in collection and assembly of clinical data. JZ, LYF, SHY, ZZ, WX, MMD, ZJL, ZFL participated in data analysis and interpretation. ZJ, MMD and BX involved in manuscript writing. ZJ, ZML, YQS, BX participated in study supervision. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Zhiming Li or Yuqin Song or Bing Xu.

Ethics declarations

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Patients and methods.

Additional file 2: Table S1.

Treatment pattern and clinical response overview based on distinct therapeutic approaches.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zha, J., Fan, L., Yi, S. et al. Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China. J Hematol Oncol 14, 131 (2021). https://doi.org/10.1186/s13045-021-01139-6

Download citation

Keywords

  • Follicular lymphoma (FL)
  • Chinese
  • Rituximab
  • Chemotherapy
  • Histological transformation (HT)